An official new study has confirmed that mRNA Covid jabs cause deadly blood clots in the lungs of recipients.
According to a recently published case study, a 26-year-old female who had just received the Pfizer Covid jab went on to be diagnosed with acute extensive pulmonary embolism (the blockage of an artery in the lungs by a substance that has moved from elsewhere in the body through the bloodstream).
“Our report however portrays a case of a 26-year-old female who developed extensive pulmonary embolism following administration of the Pfizer- BNT162b2 mRNA COVID-19 vaccine. The patient did not have any risk factors for thromboembolism,” the case study declared in the ‘Abstract’ section.
26 year old female admitted to the intensive care unit after she developed an extensive pulmonary embolism four days after 2nd dose of the #Pfizer #mRNA vaccine.https://t.co/Si1FCZOUwA pic.twitter.com/0j0lrkb0ON
— They Keep Saying Its Rare (@mRNAdeaths) August 8, 2024
Infowars.com reports: Despite facing a potentially life threatening side effect, the patient’s condition improved following treatment with several drugs.
“She was admitted, put on enoxaparin, and given Altaplase thrombolytic therapy. Her condition improved and she was discharged on Apixaban. The Thrombophilia screen performed on the 6-month follow-up was negative and following the resolution of thrombosis, Apixaban was stopped,” the case study said in the ‘Abstract’ section.
Ironically, the researchers led off by lauding the Covid vaccine, then saying they are proven to cause these ailments and ending by saying the vaccinated should be monitored for such ailments. A problem, reaction, solution dialectic.
“COVID-19 vaccines, a cornerstone of the fight against the disease have generally proven to be safe with most commonly reported side effects being mild and self-limiting. Uncommon severe adverse effects like thromboembolism have been reported during postmarketing surveillance,” the case study said in the ‘Abstract’ section. “Our case highlights the importance of continued surveillance of uncommon adverse effects and the need for prompt diagnosis and management of such side effects.”
